ATTAIN: Peginterferon beta-1a remains efficacious for MS in long term
VANCOUVER – Peginterferon beta-1a has durable efficacy for the treatment of relapsing-remitting multiple sclerosis, according to data from the ATTAIN extension study of a phase III trial.
With...
Source: Clinical Neurology News - Category: Neurology Source Type: news